Long-term Mortality and Health-related Quality of Life with Lower Versus Higher Oxygenation Targets in Intensive Care Unit Patients with COVID-19 and Severe Hypoxaemia

Purpose: The aim of this study was to evaluate one-year outcomes of lower versus higher oxygenation targets in intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.

Methods: We conducted pre-planned analyses of one-year mortality and health-related quality of life (HRQoL) in the Handling Oxygenation Targets in COVID-19 trial. The trial randomised 726 ICU patients with COVID-19 and hypoxaemia to partial pressure of arterial oxygen targets of 8 kPa (60 mmHg) versus 12 kPa (90 mmHg) during ICU stay up to 90 days, including readmissions. HRQoL was assessed using EuroQol visual analogue scale (EQ-VAS) and 5-level 5-dimension questionnaire (EQ-5D-5L). Outcomes were analysed in the intention-to-treat population. Non-survivors were assigned the worst possible score (zero), and multiple imputation was applied for missing EQ-VAS values.

Results: We obtained one-year vital status for 691/726 (95.2%) of patients and HRQoL data for 642/726 (88.4%). At one year, 117/348 (33.6%) of patients in the lower-oxygenation group had died compared to 134/343 (39.1%) in the higher-oxygenation group (adjusted risk ratio: 0.85; 98.6% confidence interval (CI) 0.66-1.09; p = 0.11). Median EQ-VAS was 50 (interquartile range, 0-80) versus 40 (0-75) (adjusted mean difference: 4.8; 98.6% CI - 2.2 to 11.9; p = 0.09) and EQ-5D-5L index values were 0.61 (0-0.81) in the lower-oxygenation group versus 0.43 (0-0.79) (p = 0.20) in the higher-oxygenation group, respectively.

Conclusion: Among adult ICU patients with COVID-19 and severe hypoxaemia, one-year mortality results were most compatible with benefit of the lower oxygenation target, which did not appear to result in more survivors with poor quality of life.

Citing Articles

Less is best for oxygen therapy in adults in the intensive care unit with severe hypoxaemia due to COVID-19.

Young P Intensive Care Med. 2024; 50(10):1685-1687.

PMID: 39264414 DOI: 10.1007/s00134-024-07554-w.

References

Mart M, Semler M, Jenkins C, Wang G, Casey J, Wesley Ely E . Oxygen-Saturation Targets and Cognitive and Functional Outcomes in Mechanically Ventilated Adults. Am J Respir Crit Care Med. 2024; 209(7):861-870. PMC: 10995564. DOI: 10.1164/rccm.202310-1826OC. View

Rasmussen B, Klitgaard T, Perner A, Brand B, Hildebrandt T, Siegemund M . Oxygenation targets in ICU patients with COVID-19: A post hoc subgroup analysis of the HOT-ICU trial. Acta Anaesthesiol Scand. 2021; 66(1):76-84. PMC: 8653379. DOI: 10.1111/aas.13977. View

Alhazzani W, Evans L, Alshamsi F, Moller M, Ostermann M, Prescott H . Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med. 2021; 49(3):e219-e234. DOI: 10.1097/CCM.0000000000004899. View

Schulz K, Altman D, Moher D . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010; 8:18. PMC: 2860339. DOI: 10.1186/1741-7015-8-18. View

Angus D, Carlet J . Surviving intensive care: a report from the 2002 Brussels Roundtable. Intensive Care Med. 2003; 29(3):368-77. DOI: 10.1007/s00134-002-1624-8. View

Soriano J, Murthy S, Marshall J, Relan P, Diaz J . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2021; 22(4):e102-e107. PMC: 8691845. DOI: 10.1016/S1473-3099(21)00703-9. View

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10):1727-36. PMC: 3220807. DOI: 10.1007/s11136-011-9903-x. View

DEttorre G, Vassalini P, Coppolelli V, Gentilini Cacciola E, Sanitinelli L, Maddaloni L . Health-related quality of life in survivors of severe COVID-19 infection. Pharmacol Rep. 2022; 74(6):1286-1295. PMC: 9662770. DOI: 10.1007/s43440-022-00433-5. View

Higgins A, Berry L, Lorenzi E, Murthy S, McQuilten Z, Mouncey P . Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA. 2022; 329(1):39-51. PMC: 9857594. DOI: 10.1001/jama.2022.23257. View

10.

Frat J, Quenot J, Badie J, Coudroy R, Guitton C, Ehrmann S . Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19: The SOHO-COVID Randomized Clinical Trial. JAMA. 2022; 328(12):1212-1222. PMC: 9516287. DOI: 10.1001/jama.2022.15613. View

11.

Jensen C, Sorensen S, Gudex C, Jensen M, Pedersen K, Ehlers L . The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data. Appl Health Econ Health Policy. 2021; 19(4):579-591. PMC: 8270796. DOI: 10.1007/s40258-021-00639-3. View

12.

DEttorre G, Gentilini Cacciola E, Santinelli L, De Girolamo G, Spagnolello O, Russo A . Covid-19 sequelae in working age patients: A systematic review. J Med Virol. 2021; 94(3):858-868. PMC: 8661973. DOI: 10.1002/jmv.27399. View

13.

Colantuoni E, Li X, Hashem M, Girard T, Scharfstein D, Needham D . A structured methodology review showed analyses of functional outcomes are frequently limited to "survivors only" in trials enrolling patients at high risk of death. J Clin Epidemiol. 2021; 137:126-132. PMC: 8464482. DOI: 10.1016/j.jclinepi.2021.03.027. View

14.

Ospina-Tascon G, Calderon-Tapia L, Garcia A, Zarama V, Gomez-Alvarez F, Alvarez-Saa T . Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021; 326(21):2161-2171. PMC: 8652598. DOI: 10.1001/jama.2021.20714. View

15.

Nielsen F, Klitgaard T, Crescioli E, Aagaard S, Andreasen A, Poulsen L . Handling oxygenation targets in ICU patients with COVID-19-Protocol and statistical analysis plan in the HOT-COVID trial. Acta Anaesthesiol Scand. 2021; 65(10):1497-1504. PMC: 8441913. DOI: 10.1111/aas.13956. View

16.

Bitterman H . Bench-to-bedside review: oxygen as a drug. Crit Care. 2009; 13(1):205. PMC: 2688103. DOI: 10.1186/cc7151. View

17.

Nielsen F, Klitgaard T, Siegemund M, Laake J, Thormar K, Cole J . Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19: The HOT-COVID Randomized Clinical Trial. JAMA. 2024; 331(14):1185-1194. PMC: 10951852. DOI: 10.1001/jama.2024.2934. View

18.

Schjorring O, Klitgaard T, Perner A, Wetterslev J, Lange T, Siegemund M . Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure. N Engl J Med. 2021; 384(14):1301-1311. DOI: 10.1056/NEJMoa2032510. View

19.

Schjorring O, Perner A, Wetterslev J, Lange T, Keus F, Laake J . Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU)-Protocol for a randomised clinical trial comparing a lower vs a higher oxygenation target in adults with acute hypoxaemic respiratory failure. Acta Anaesthesiol Scand. 2019; 63(7):956-965. DOI: 10.1111/aas.13356. View

20.

Jakobsen J, Gluud C, Wetterslev J, Winkel P . When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol. 2017; 17(1):162. PMC: 5717805. DOI: 10.1186/s12874-017-0442-1. View